Synthesis of Some New Xanthine Derivatives and Evaluation of DPP IV Inhibitory Activities
Archiv der Pharmazie · 2026
DOI: 10.1002/ardp.70362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Erol Akgün und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Graduate Education, Pharmaceutical Chemistry, Anadolu University, Eskişehir, Turkey. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Dipeptidyl Peptidase 4, Xanthines. Die Arbeit nennt 59 Literaturangaben. Gefördert von: Anadolu University Scientific Research Project Coordination.
Abstract (Originalsprache)
Dipeptidyl peptidase IV (DPP IV) inhibition prolongs incretin activity and represents an established therapeutic strategy for the management of type 2 diabetes mellitus. To investigate the underexplored combination of benzyl groups at the N7 position and a piperazine‐linked arylthiazole moiety at the C8 position of the xanthine scaffold, 15 novel compounds ( 6a–6o ) were synthesised. The synthetic route involved bromination at the C8 position of theophylline, introduction of benzyl groups at the N7 position, replacement of the bromine atom at the C8 position with piperazine, and subsequent cyclocondensation with phenacyl thiocyanate derivatives. All final compounds were characterised by 1 H and 13 C NMR spectroscopy, high‐resolution accurate‐mass mass spectrometry, and analytical HPLC. All derivatives inhibited DPP IV in the low‐nanomolar range, with compounds 6c and 6b showing the highest activities, with IC 50 values of 3.95 ± 0.53 and 4.04 ± 0.65 nM, respectively. NIH3T3 cytotoxicity IC 50 values ranged from 28.52 to 397.63 µM, indicating substantial preliminary concentration margins relative to DPP IV inhibition. Molecular docking, 100 ns molecular dynamics simulations, interaction‐fingerprint analyses and trajectory‐based MM/PBSA calculations supported persistent interactions with key DPP IV active‐site residues. These results identify the synthesised derivatives, particularly 6b and 6c , as promising lead structures for further optimisation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Graduate Education, Pharmaceutical Chemistry, Anadolu University, Eskişehir, Turkey.
- Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Marmara University, Istanbul, Turkey.
- Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Anadolu University, Eskişehir, Turkey.
- Faculty of Pharmacy, Department of Pharmaceutical Microbiology, Istanbul Medipol University, Istanbul, Turkey.
- Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Istanbul Okan University, Istanbul, Turkey.
ORCID-Profile: Erol Akgün, Leyla Yurttaş, Sevde Nur Biltekin Kaleli, Derya Osmaniye
Förderung
- Anadolu University Scientific Research Project Coordination
Zitieren
APA
Akgün, E., Yurttaş, L., Kaleli, S. N. B., Osmaniye, D., Berk, B., & Demirayak, Ş. (2026). Synthesis of Some New Xanthine Derivatives and Evaluation of DPP IV Inhibitory Activities. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70362
Vancouver
Akgün E, Yurttaş L, Kaleli SNB, Osmaniye D, Berk B, Demirayak Ş. Synthesis of Some New Xanthine Derivatives and Evaluation of DPP IV Inhibitory Activities. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70362
BibTeX
@article{Akgn2026,
author = {Akgün, Erol and Yurttaş, Leyla and Kaleli, Sevde Nur Biltekin and Osmaniye, Derya and Berk, Barkın and Demirayak, Şeref},
title = {Synthesis of Some New Xanthine Derivatives and Evaluation of DPP IV Inhibitory Activities},
journal = {Archiv der Pharmazie},
year = {2026},
doi = {10.1002/ardp.70362}
}
EUVIMED